Opportunity and Strategy Analysis
This report focuses on identifying opportunities and strategies for investing in the global mRNA therapeutics market within the forecast period. It provides a complete analysis of the global market both quantitatively and qualitatively. The quantitative analysis includes market size and revenue data of the total demand, sub-markets, and regional/national levels throughout 2023-2033. Qualitative analysis depicts a full picture of market dynamics and trends including drivers, restraints and challenges, emerging products/market trends, and Porter’s Fiver Forces analysis.

Based on the market data and analysis, the report highlights Increasingly Attractive Segments (IAS) and business opportunities in each segmentation. Moreover, a systematic evaluation of Internal Risks (factors arising within the industry development) and External Risks (factors arising from the surrounding environments) is provided for the mRNA therapeutics industry and market. All the identified risk factors are measured quantitatively according to GMD’s novel numeric system, i.e. each risk is evaluated with GMD Risk Index Number (GMD RIN) and GMD Risk Intensity Level (GMD RIL). This in-depth risk assessment offers a comprehensive understanding of the current risk factors and their developing trends. Furthermore, this report concludes risk management strategies and Critical Success Factors (CSFs) to help companies make intelligence-based business decisions in the global mRNA therapeutics industry.

Market Coverage & Overview
The report is based on studies for 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. Considering impact of COVID-19 and regional conflicts such as Russia-Ukraine war, the trend and outlook of global market is forecast in optimistic, balanced, and conservative scenarios. In the balanced view, the global mRNA therapeutics market is expected to reach $135.17 billion by 2033, growing by 16.1% annually over the coming years.

Segmentation Analysis
Highlighted with 89 tables and 92 figures, this 177-page report represents a 360-degree view on the global market with extensively detailed segmentations by Product, mRNA Type, Application, End User, and Region/Country as shown below. Annual revenue 2023-2033 for each segment is included in the report.

By Product

  • Prophylactic Vaccines
  • Therapeutic Vaccines
  • Therapeutic Drugs



By mRNA Type

  • Self-amplifying mRNA
  • Nucleoside-modified mRNA
  • Unmodified mRNA



By Application

  • Oncology


o Personalized Treatment
o Single Cancer Treatment

  • Respiratory Diseases
  • Infectious Diseases
  • Autoimmune Diseases
  • Rare Genetic Diseases
  • Other Applications



By End User

  • Hospitals and Clinics
  • Research Organizations
  • Other End Users



By Region

  • North America (U.S., Canada, and Mexico)
  • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
  • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
  • South America (Brazil, Colombia, Argentina, Rest of South America)
  • MEA (UAE, Saudi Arabia, Israel, and Rest of MEA)


The breakdown of all regional markets by country and the breakdown of each national market by Product, Application, and End User over the forecast years are also included.

Key Companies
The report also covers the current competitive scenario and profiles key vendors including market leaders and important emerging players. A selection of companies profiled in this report includes:

  • Arcturus Therapeutics
  • Argos Therapeutics Inc.
  • AstraZeneca Plc
  • BioNTech SE
  • CRISPR Therapeutics AG
  • CureVac AG
  • eTheRNA
  • Ethris GMBH
  • GlaxoSmithKline PLC
  • Moderna Therapeutics Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics Inc.
  • Translate Bio Inc.